



November 24, 2015

VBSE Limited

Department of Corporate Services,
1st Floor, New Trading Ring,
Rotunda Building, Dalal Street,
MUMBAI - 400 001.

The National Stock Exchange of India Limited

Exchange Plaza,
Bandra Kurla Complex,
Bandra (East),
MUMBAI - 400 051.

Dear Sirs,

Sub: Disclosure pursuant to Clause 36 of the Listing Agreement.

Enclosed is a press release as regards receipt of final USFDA approvals for Blisovi[®] Fe 1/20 and 1.5/30 Tablets, to market the AB rated generic versions of Warner Chilcott's Loestrin[®] Fe 1/20 and Fe 1.5/30 Tablets, indicated for prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Lupin Pharmaceuticals Inc., U.S.A., wholly-owned subsidiary of the Company, shall shortly commence promoting the product in the US.

This may be considered as a disclosure pursuant to Clause 36 of the Listing Agreement.

Thanking you,

Yours faithfully,
For **LUPIN LIMITED**


R. V. SATAM
COMPANY SECRETARY & COMPLIANCE OFFICER

Encl: a/a.



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

Lupin Receives FDA Approvals for Generic Loestrin® Fe 1/20 and Loestrin® 1.5/30 Tablets

Mumbai, Baltimore, November 24, 2015: Pharma Major Lupin Limited (Lupin) announced today that it has received final approvals for its **Blisovi® Fe 1/20 Tablets** (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) and **Blisovi® 1.5/30 Tablets** (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg) from the United States Food and Drug Administration (FDA) to market generic versions of Warner Chilcott's **Loestrin® Fe 1/20 Tablets** (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1 mg/0.02 mg and Ferrous Fumarate Tablets, 75 mg) and **Loestrin® Fe 1.5/30 Tablets** (Norethindrone Acetate and Ethinyl Estradiol Tablets USP, 1.5 mg/0.03 mg and Ferrous Fumarate Tablets, 75 mg). Lupin's US subsidiary, Lupin Pharmaceuticals Inc. shall commence promoting the product in the US shortly.

Lupin's Blisovi® Fe 1/20 Tablets and Blisovi® 1.5/30 Tablets are the AB rated generic equivalent of Warner Chilcott's Loestrin® Fe 1/20 Tablets and Loestrin® Fe 1.5/30 Tablets and are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.

Loestrin® Fe 1/20 had US sales of **USD 139.7 million** (IMS MAT September 2015) while Loestrin® Fe 1.5/30 had US sales of **USD 55.5 million** (IMS MAT September 2015).

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 6th largest generic pharmaceutical player in the US (5.5% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales globally. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan (ranked 8th) and South Africa (ranked 4th – IMS Health). For the financial year ended 31st March 2015, Lupin's Consolidated turnover and Profit after Tax were Rs. 125,997 million (USD 2.06 billion) and Rs. 24,032 million (USD 393 million) respectively.

About Lupin Pharmaceuticals Inc. (LPI)

Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies.

For more information on **Lupin Limited**, please visit <http://www.lupin.com>. You could also follow us on Twitter – www.twitter.com/lupinlimited

For more information on **LPI**, please visit <http://www.lupinpharmaceuticals.com>

CIN: L24100MH1983PLC029442 Registered Office: 159, C.S.T. Road, Kalina, Santacruz (East), Mumbai - 400 098

Press Release



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

For further information or queries please contact -

Shamsher Gorawara
Head – Corporate Communications
Lupin Limited
Ph: +91 98 20 338 555
Email: shamshergorawara@lupin.com

or

Alpesh Dalal
Head – M & A and Investor Relations
Lupin Limited
Ph: +91 98 20 023 511
Email: alpeshdalal@lupin.com

[Safe Harbor Statement](#)

Loestrin® is a registered trademark of Warner Chilcott Company, LLC.